Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8Gastrointestinal 4Breast 3Tumor-Agnostic 2Thoracic 2Other neoplasm 2Head & Neck 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Non-melanoma Skin Cancer 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Vitamin E × Dermatologic × Clear all
NCT00392561 2023-04-26

BEST

University of Chicago

Phase NA Completed
7,000 enrolled
Dermatologic

Non-melanoma Skin Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡